Complex Medicines: 
Selection and Characterisation of the Lead

18 May 2021  |  2 - 3PM BST

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.

© Medicines Discovery Catapult 2021. All rights reserved. Read our Privacy Policy


Developing the assay cascade for complex medicines - Tilly Bingham (Concept Life Sciences)
CryoEM in characterisation and quality control of complex medicines - Rebecca Thompson (Astbury Biostructure Laboratory)
Cellular internalisation and trafficking of complex medicines - Dr Jamie Szczerkowski, Postdoc Scientist - Advanced Microscopy (MDC)





Complex Medicines: Understanding Safety & Efficacy
15 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Understanding the Interplay with Biological Systems
25 May 2021  |  2 - 3PM BST
Register >

Complex Medicines: Ready for the Clinic/Scaling up for Success
22 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: A Glance at Novel Drug Delivery Systems
8 June 2021  |  2 - 3PM BST
Register >

Complex Medicines: Why, What, When? Opportunities and Challenges
11 May 2021  |  2 - 3PM BST
Register >

Dr Sarah Brockbank
Sarah Brockbank is Lead Scientist of External Drug Discovery at the Medicines Discovery Catapult. Here she supports SMEs develop and execute drug discovery projects and provides the project management of virtual preclinical programmes by connecting clients with expertise and capabilities.

Sarah has 30 years’ experience in the pharmaceutical industry. She is a molecular biologist with a focus mainly in target identification & validation and has worked across a broad range of disease areas. Sarah was a Drug Discovery Project Leader at AstraZeneca and she also has extensive experience in collaboration management and project management of large public-private consortia.

In this session, we will look at assays, technologies and capabilities which can be employed to characterise the lead molecule.

Tilly Bingham
Tilly Bingham is VP Science at Concept Life Sciences with over 18 years’ experience in the pharmaceutical sector in ‘large pharma’ (Organon, Schering-Plough, MSD), Biotech (Redx Pharma) and currently with a CRO (Concept Life Sciences). Her early career was spent working in CNS therapeutic areas. More recently as Head of Research and Operations at Redx Pharma she was involved in the discovery and development of oncology and fibrosis clinical and pre-clinical candidates including the porcupine inhibitor RXC004 and BTK inhibitor LOXO-305. She is currently VP Science overseeing multiple programs covering the pharmaceutical, agrochemical and petrochemicals sectors.

Rebecca Thompson
Rebecca is the Head of Faculty Biological Sciences Research Facilities and Deputy Director Asbury, University of Leeds. In this role, she oversees the management of a range of research facilities, including cryo-electron microscopy capabilities with two state-of-the-art Titan Krios microscopes. Her current research interests span cryo-electron microscopy and include developing and optimising workflows for high-resolution structure determination of macromolecular complexes by single-particle analysis and using cryo-electron tomography to image cells and organelles.

Dr Jamie Szczerkowski
Jamie is a Postdoctoral Scientist in Advanced Microscopy with Medicines Discovery Catapult, helping support projects through experiments design, image acquisition and analysis.

He acquired a PhD from King’s College London defining the dynamics of mitochondrial networks during Wnt3a-mediated asymmetric cell division of mouse embryonic stem cells. He utilised a myriad of microscopy techniques, development of custom scripts for image analysis and data extraction. From automated pipelines to high-throughput screening, 3D cellular reconstruction, subcellular distribution and tracking, the characterisation and morphology changes of cells in real time as they interact with their environment.